Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Chantil Jeffreys

Nurse Practitioner, Family Germantown, TN Nurse Practitioner

NPI 1942285465 CMS profile 11121803

8000 Wolf River Blvd Ste 200, Germantown, TN 38138

Open in the dashboard

General payments

$194,591

988 records reported · program years 2021–2025

Research payments

$1,492

Paid to them · 11 records reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chantil Jeffreys of Germantown, TN is reported in the CMS Open Payments database as having received $194,591 across 988 general payments and $1,492 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $69,197 301
2024 General $84,552 344
2023 General $16,819 136
2023 Research $1,492 11
2022 General $14,854 146
2021 General $9,169 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chantil Jeffreys
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Chantil Jeffreys were reported at $69,197. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Chantil Jeffreys Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $9,169 $124 $35–$379 $132
2022 $14,854 $141 $44–$430 $149
2023 $16,819 $154 $49–$476 $160
2024 $84,552 $165 $51–$504 $164
2025 $69,197 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $39,304 108 payments
  2. Intercept Pharmaceuticals, Inc. $33,130 97 payments
  3. Phathom Pharmaceuticals, Inc. $31,081 82 payments
  4. Ipsen Biopharmaceuticals, Inc $15,813 32 payments
  5. Novo Nordisk Inc $13,254 17 payments
  6. Madrigal Pharmaceuticals $13,212 49 payments
  7. Gilead Sciences, Inc. $12,002 53 payments
  8. Enterra Medical, Inc. $9,544 14 payments
  9. Ardelyx, Inc. $9,340 40 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $5,493 75 payments
  11. Other $12,418 421 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $89,482 84 payments
  2. Travel and Lodging $50,044 100 payments
  3. Food and Beverage $22,180 755 payments
  4. Consulting Fee $13,660 15 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $13,165 15 payments
  6. Honoraria $5,705 12 payments
  7. Education $354 7 payments
Products named General payments · program years 2021–2025
  1. VOQUEZNA $30,804 72 payments
  2. OCALIVA Hepatology / Gastroenterology $27,910 74 payments
  3. OMVOH $23,208 69 payments
  4. IQIRVO $13,626 26 payments
  5. Wegovy $13,136 16 payments
  6. IBSRELA $9,340 40 payments
  7. REZDIFFRA $8,585 19 payments
  8. XIFAXAN $8,070 66 payments
  9. Epclusa $7,131 13 payments
  10. OCALIVA Hepatology Gastroenterology $5,165 22 payments
  11. Other $27,598 663 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Sanofi US Services Inc. $1,492 11 payments

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

656

Median for Nurse Practitioner: 389

Drug cost

$296,775

Median for Nurse Practitioner: $21,885

Branded share of claims

28.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 47 $148,711
Xifaxan Rifaximin Brand 16 $38,070
Linzess Linaclotide Brand 28 $31,893
Zenpep Lipase/Protease/Amylase Brand 12 $26,236
Viberzi Eluxadoline Brand 19 $24,508
Mesalamine Generic 13 $6,077
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 24 $3,918
Promethazine Hcl Generic 27 $3,583
Balsalazide Disodium Generic 12 $2,657
Esomeprazole Magnesium Generic 41 $2,098

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$62,425

Medicare's payments for the services billed

Medicare patients

324

Average age 73

Services billed

1,868

207 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 35%
Ischemic heart disease 34%
Chronic kidney disease 23%
Depression 22%
Osteoporosis 19%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
$27,906 — —
OMVOH
$21,962 — —
REZDIFFRA
$8,585 — —
IQIRVO
$2,806 — —
XIFAXAN
$875 16 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

999 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record